Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Bacteria’s Self-Defense Mechanisms Revealed

By BiotechDaily International staff writers
Posted on 24 Sep 2012
Image: The toxins normally bind very strongly to the antitoxins and are thus not only inactive, but also prevent the production of more toxin from the information encoded in the bacterial DNA. During the dormant state, however, the antitoxins are degraded, and the toxins released (step 1). The free toxins now bind to unoccupied antitoxins on DNA within the area encoding the toxin-antitoxin couple (step 2). Binding increasing amounts of toxin eventually leads to the release of the molecules from the gene (steps 3 and 4) and finally to new toxin production (Photo courtesy of Ditlev E. Brodersen).
Image: The toxins normally bind very strongly to the antitoxins and are thus not only inactive, but also prevent the production of more toxin from the information encoded in the bacterial DNA. During the dormant state, however, the antitoxins are degraded, and the toxins released (step 1). The free toxins now bind to unoccupied antitoxins on DNA within the area encoding the toxin-antitoxin couple (step 2). Binding increasing amounts of toxin eventually leads to the release of the molecules from the gene (steps 3 and 4) and finally to new toxin production (Photo courtesy of Ditlev E. Brodersen).
Danish researchers have gleaned new insights into how bacteria control the amount of toxin in their cells. The new findings can ultimately lead to the development of novel forms of treatment for bacterial infections.

Many pathogenic bacteria are able to go into a dormant state by making persister cells that are not receptive to conventional antibiotics. This causes serious problems in the treatment of life-threatening disorders such as tuberculosis, where the presence of persister cells often leads to a resurgence of infection following medical treatment.

At the molecular level, the formation of persister cells is due to the presence of toxins that are produced by the bacteria themselves, and which enable them to enter the dormant state. During this hibernation period, the bacteria constantly regulate the amount of toxin at exactly the same level and thus maintain the dormant state.

In an article published online August 20, 2012, in the American scientific journal Structure, the researchers from the department of molecular biology and genetics, Aarhus University (Aarhus, Denmark), new findings that reveal the molecular particulars of the regulatory mechanism of toxins.

By isolating and crystallizing the toxin molecules and their molecular companions--the antitoxins--and by subsequently exposing the crystals to strong X-rays, the scientists gained unique insight into how bacteria control the amount of toxin in the cell.

The new findings can eventually lead to the development of completely new forms of treatment of bacterial infections that work at first by blocking toxin function and production, and consequently by using conventional antibiotics to fight the pathogenic bacteria.

Related Links:
Aarhus University


Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.